FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087884039> ?p ?o ?g. }

• W2087884039 endingPage "1025" @default.
• W2087884039 startingPage "1016" @default.
• W2087884039 abstract "The aim of this study was to evaluate the efficacy of docetaxel as first-line chemotherapy in patients with unresectable metastatic or locally advanced pancreatic adenocarcinoma and to further characterise the safety and pharmacokinetic profiles of docetaxel. 43 patients were enrolled into this phase II study. Treatment consisted of a 1-h infusion of docetaxel 100 mg/m2 every 3 weeks without premedication with corticosteroids until progression or unacceptable toxicity occurred. Dose modifications were planned for adverse events. Patients were observed for 1 month after the last docetaxel infusion, to document any late adverse events, with a follow-up every 3 months until death. Response rate and duration were the major efficacy endpoints. Response status was reviewed by an external independent panel. Pharmacokinetic analysis was performed during the first treatment cycle. 40 patients were evaluable for response, and all were evaluable for safety. After independent review, partial response was recorded in 6 patients (overall response rate, 15%; 95% confidence limit (CI), 7.7-29.8%) and stable disease was recorded in 15 patients (38%). The median duration of response was 5.1 months (range: 3.1-7.2). The median pain control time was 4.5 months (range: 0-8) and the median time to performance status worsening was 2.3 months (range: 0-4.5). Most patients 40 (93.0%) received a relative dose intensity of more than 70% of the planned dose. The incidence and severity of adverse events reflected the known safety profile for docetaxel. Docetaxel clearance was reduced in patients with elevated concentrations of hepatic enzymes or bilirubin. Docetaxel is an active agent for unresectable metastatic or locally advanced pancreatic adenocarcinoma." @default.
• W2087884039 created "2016-06-24" @default.
• W2087884039 creator A5008370341 @default.
• W2087884039 creator A5026512478 @default.
• W2087884039 creator A5036517195 @default.
• W2087884039 creator A5041588416 @default.
• W2087884039 creator A5060246054 @default.
• W2087884039 creator A5068106161 @default.
• W2087884039 creator A5082689339 @default.
• W2087884039 creator A5085121407 @default.
• W2087884039 creator A5085201814 @default.
• W2087884039 creator A5087225597 @default.
• W2087884039 creator A5088571280 @default.
• W2087884039 creator A5089377108 @default.
• W2087884039 date "2000-05-01" @default.
• W2087884039 modified "2023-10-16" @default.
• W2087884039 title "A phase II study" @default.
• W2087884039 cites W1931508686 @default.
• W2087884039 cites W1964104588 @default.
• W2087884039 cites W1968837173 @default.
• W2087884039 cites W1968965382 @default.
• W2087884039 cites W1971197495 @default.
• W2087884039 cites W1978228326 @default.
• W2087884039 cites W1978876237 @default.
• W2087884039 cites W1979374714 @default.
• W2087884039 cites W1984254136 @default.
• W2087884039 cites W1994069365 @default.
• W2087884039 cites W2018473224 @default.
• W2087884039 cites W2029409133 @default.
• W2087884039 cites W2041889651 @default.
• W2087884039 cites W2043288781 @default.
• W2087884039 cites W2043478531 @default.
• W2087884039 cites W2044313019 @default.
• W2087884039 cites W2046772809 @default.
• W2087884039 cites W2049969048 @default.
• W2087884039 cites W2050088084 @default.
• W2087884039 cites W2067299834 @default.
• W2087884039 cites W2073533584 @default.
• W2087884039 cites W2084243210 @default.
• W2087884039 cites W2084562398 @default.
• W2087884039 cites W2126871433 @default.
• W2087884039 cites W2128889451 @default.
• W2087884039 cites W2135352785 @default.
• W2087884039 cites W2151767652 @default.
• W2087884039 cites W2151906733 @default.
• W2087884039 cites W2228636571 @default.
• W2087884039 cites W2285738680 @default.
• W2087884039 cites W2289397400 @default.
• W2087884039 cites W2321029249 @default.
• W2087884039 cites W4244373493 @default.
• W2087884039 doi "https://doi.org/10.1016/s0959-8049(00)00072-1" @default.
• W2087884039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10885606" @default.
• W2087884039 hasPublicationYear "2000" @default.
• W2087884039 type Work @default.
• W2087884039 sameAs 2087884039 @default.
• W2087884039 citedByCount "246" @default.
• W2087884039 countsByYear W20878840392012 @default.
• W2087884039 countsByYear W20878840392013 @default.
• W2087884039 countsByYear W20878840392014 @default.
• W2087884039 countsByYear W20878840392015 @default.
• W2087884039 countsByYear W20878840392016 @default.
• W2087884039 countsByYear W20878840392017 @default.
• W2087884039 countsByYear W20878840392019 @default.
• W2087884039 countsByYear W20878840392020 @default.
• W2087884039 countsByYear W20878840392023 @default.
• W2087884039 crossrefType "journal-article" @default.
• W2087884039 hasAuthorship W2087884039A5008370341 @default.
• W2087884039 hasAuthorship W2087884039A5026512478 @default.
• W2087884039 hasAuthorship W2087884039A5036517195 @default.
• W2087884039 hasAuthorship W2087884039A5041588416 @default.
• W2087884039 hasAuthorship W2087884039A5060246054 @default.
• W2087884039 hasAuthorship W2087884039A5068106161 @default.
• W2087884039 hasAuthorship W2087884039A5082689339 @default.
• W2087884039 hasAuthorship W2087884039A5085121407 @default.
• W2087884039 hasAuthorship W2087884039A5085201814 @default.
• W2087884039 hasAuthorship W2087884039A5087225597 @default.
• W2087884039 hasAuthorship W2087884039A5088571280 @default.
• W2087884039 hasAuthorship W2087884039A5089377108 @default.
• W2087884039 hasConcept C120665830 @default.
• W2087884039 hasConcept C121332964 @default.
• W2087884039 hasConcept C126322002 @default.
• W2087884039 hasConcept C141071460 @default.
• W2087884039 hasConcept C197934379 @default.
• W2087884039 hasConcept C2776694085 @default.
• W2087884039 hasConcept C2778300832 @default.
• W2087884039 hasConcept C2781190966 @default.
• W2087884039 hasConcept C61511704 @default.
• W2087884039 hasConcept C71924100 @default.
• W2087884039 hasConceptScore W2087884039C120665830 @default.
• W2087884039 hasConceptScore W2087884039C121332964 @default.
• W2087884039 hasConceptScore W2087884039C126322002 @default.
• W2087884039 hasConceptScore W2087884039C141071460 @default.
• W2087884039 hasConceptScore W2087884039C197934379 @default.
• W2087884039 hasConceptScore W2087884039C2776694085 @default.
• W2087884039 hasConceptScore W2087884039C2778300832 @default.
• W2087884039 hasConceptScore W2087884039C2781190966 @default.
• W2087884039 hasConceptScore W2087884039C61511704 @default.
• W2087884039 hasConceptScore W2087884039C71924100 @default.

• next